Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Okami Medical Announces FDA 510(k) Clearance of the LOBO-5 Vascular Occluder


ALISO VIEJO, Calif., Dec. 16, 2020 /PRNewswire/ -- Okami Medical Inc., a medical device company, today announced the expansion of its LOBOtm Vascular Occlusion System product line with the U.S. FDA 510(k) clearance of the LOBO-5 Vascular Occluder. 

The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, "one-and-done" solution for the occlusion of a wide range of peripheral arterial targets.  The LOBO system combines neurovascular-derived HDBRAIDtm technology with a patented design to create a highly occlusive structure for fast and efficient closure of blood vessels throughout the body.  LOBO-5, the second offering in the company's product portfolio, is intended for use in 3 to 5 mm diameter vessels.  LOBO-3, the company's first occluder, is intended for use in 1.5 to 3 mm vessels.  The LOBO system is demonstrated in a newly released animation on the Okami Medical website (www.okamimedical.com).

"The FDA clearance of LOBO-5 marks another milestone in our mission to provide patients and physicians with access to advanced technologies that address the numerous unmet clinical needs in peripheral vascular occlusion," said Bob Rosenbluth, PhD, President and CEO of Okami Medical.  "LOBO-3 and LOBO-5, to be followed by LOBO-7 and LOBO-9, are designed and built to enable fast, predictable and complete occlusion of a diverse set of vascular targets without the need for multiple embolic devices."  

About Okami Medical

Okami Medical, Inc. is a privately-held medical device company with a mission to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels. The company was created in 2017 by Inceptus Medical, a medical device incubator. Okami is backed by members of the board of directors, U.S. Venture Partners (www.usvp.com) and medical device industry veterans. For more information, please visit www.okamimedical.com.

SOURCE Okami Medical Inc.


These press releases may also interest you

at 12:05
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:02
On May 1, 2024, Toronto Public Health (TPH) will host Diverse Dialogues: Stigma & Breaking Barriers. The event will bring together distinguished speakers to explore the challenging and thought-provoking topic about how negative labels and biases...

at 11:56
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....



News published on and distributed by: